Ratings
0
Nobody has rated this yet. Be the first!
Works
10
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure.
Hepatotoxicity with combination of vemurafenib and ipilimumab
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
